The immune landscape of systemic sclerosis: from pathogenic mechanisms to precision therapeutic breakthroughs.

Front Immunol · 2026 · PMC12989563 · PMID 41846909

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A subgroup analysis of a global phase III trial focused on Japanese SSc-ILD patients found that tocilizumab slowed the annual rate of forced vital capacity (FVC) decline—though the effect did not reach statistical significance in the overall population ( 79 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.